The Hedgehog Pathway Inhibitors Market is expected to grow between 2024 and 2032, driven by increasing prevalence of basal cell carcinoma and other hedgehog-driven cancers, along with approval of second-generation inhibitors. Advances in combination regimens, trial-stage assets, and expanding indications are fueling market evolution in oncology targeted therapy. https://www.datamintelligence.com/research-report/a2-milk-market